Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.59 USD | -0.60% | +2.24% | -17.79% |
04-11 | North American Morning Briefing : Stock Futures -2- | DJ |
04-10 | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform | MT |
Sales 2024 * | 622M 49.82B | Sales 2025 * | 773M 61.88B | Capitalization | 6.07B 486B |
---|---|---|---|---|---|
Net income 2024 * | -573M -45.87B | Net income 2025 * | -496M -39.71B | EV / Sales 2024 * | 9.57 x |
Net cash position 2024 * | 111M 8.88B | Net Debt 2025 * | 218M 17.47B | EV / Sales 2025 * | 8.13 x |
P/E ratio 2024 * |
-10.5
x | P/E ratio 2025 * |
-12.4
x | Employees | 927 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.07% |
Latest transcript on Ionis Pharmaceuticals, Inc.
1 day | -0.60% | ||
1 week | +2.24% | ||
Current month | -4.06% | ||
1 month | -6.87% | ||
3 months | -19.23% | ||
6 months | -5.58% | ||
Current year | -17.79% |
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 30/06/12 |
Brett Monia
FOU | Founder | 62 | 09/01/89 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 30/04/00 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 02/02/14 |
Brett Monia
FOU | Founder | 62 | 09/01/89 |
Joan Herman
BRD | Director/Board Member | 70 | 09/06/19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.89% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 41.59 | -0.60% | 556,093 |
25/04/24 | 41.84 | -1.44% | 1,142,810 |
24/04/24 | 42.45 | +1.46% | 731,441 |
23/04/24 | 41.84 | +1.87% | 631,237 |
22/04/24 | 41.07 | +0.96% | 705,230 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.79% | 6.07B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IONS Stock